CellCentric

CellCentric is a clinical-stage biopharmaceutical company based in Cambridge, UK, with additional sites in Manchester and Boston. Founded in 2003, it specializes in oncology drug development through epigenetic modulation. The company is known for its lead product, inobrodib (CCS1477), a first-in-class oral p300/CBP inhibitor currently in Phase II clinical trials. This drug targets specific gene activations involved in tumor progression, particularly for multiple myeloma and other cancers. CellCentric was established by Professor Azim Surani from the University of Cambridge to explore new cancer treatments through chromatin-related mechanisms. The company collaborates with over 25 leading academic research groups to investigate various epigenetic targets. It has raised significant funding, totaling $253.9 million, and holds 48 patents in epigenetics. CellCentric's mission is to improve patient outcomes through science-driven strategies and partnerships with research centers, patient groups, and clinical trial sites across the UK, US, and EU.